STOCK TITAN

XSPRAY - XSPRAY STOCK NEWS

Welcome to our dedicated news page for XSPRAY (Ticker: XSPRAY), a resource for investors and traders seeking the latest updates and insights on XSPRAY.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XSPRAY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XSPRAY's position in the market.

Rhea-AI Summary
Xspray Pharma AB announces FDA acceptance of NDA resubmission for Dasynoc®, setting a PDUFA date for July 31, 2024. The company plans to launch the innovative CML treatment on September 1, 2024, following a patent litigation settlement with Bristol Myers Squibb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Xspray Pharma AB (XSPRAY) announced the development of XS003, an amorphous non-crystalline formulation of nilotinib, a protein kinase inhibitor (PKI) product candidate designed to address therapeutic limitations of TASIGNA®. TASIGNA is a key treatment for chronic myeloid leukemia (CML) with global sales nearing $2.0 billion in 2022. The NDA for XS003 is expected to be submitted to the US FDA in the second half of 2024. XS003 has shown bioavailability within the 80-125% range to TASIGNA following oral administration, with a significantly lower dose, demonstrating improved absorption and reduced food interactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Xspray Pharma AB (XSPRAY) announces results from drug interaction studies demonstrating that DASYNOC's uptake into blood is not altered by the concomitant administration of omeprazole, while a significant reduction in the uptake of SPRYCEL was observed. This highlights DASYNOC's significant potential to improve chronic myeloid leukemia (CML) treatment by avoiding interactions with proton pump inhibitors (PPIs) and providing patients the full therapeutic benefit of their treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
XSPRAY

Nasdaq:XSPRAY

XSPRAY Rankings

XSPRAY Stock Data